Access to Medicines at Sustainable Price: Pharma Industry and Governments Transforming Challenges into Opportunities

23 March 2017

Stimulating Investment in European Generic, Biosimilar and Value Added Medicines through a Transparent Legal Environment

22 March 2017

Key authorities, eminent lawyers and industry leaders discussed today in […]

Biosimilar interchangeability: Do you know your switching from your substitution?

21 March 2017

US FDA interchangeability guidance adds another level of confusion over […]

Some EU countries effectively delay market entry of generics

17 March 2017

The harmonisation of different regulatory environments in the EU member […]

European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World

14 March 2017

On 9th March, IFPMA launched jointly with EFPIA and EBE […]

Experience and Evidence of Physician-led Switching of Biological Medicines Fully Recognised in Europe

9 March 2017

Medicines for Europe welcomes the fact that EFPIA (supported by […]

European Parliament Recognises the Major role of Generic, Biosimilar and Value Added Medicines in Improving Access

2 March 2017

Today, the European Parliament voted on the report on ‘Options […]

Joint Declaration for an ambitious EU industrial strategy

27 February 2017

Europe is the cradle of the manufacturing industry and has […]

EU-Canada Free Trade Agreement: an Opportunity to Create Manufacturing Jobs in the Generic and Biosimilar Medicines Industries

20 February 2017

Medicines for Europe welcomes the approval by the European Parliament […]

Biosimilar medicines: Increasing access to modern essential medicines while supporting sustainability of healthcare systems

16 February 2017

Biologic medicines have revolutionised the management of many serious diseases […]